Loading...
XTAEBLRX
Market cap1mUSD
Dec 20, Last price  
5.80ILS
1D
0.00%
1Q
-64.42%
Jan 2017
-98.33%
IPO
-99.90%
Name

BioLine RX Ltd

Chart & Performance

D1W1MN
XTAE:BLRX chart
P/E
—
P/S
33.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
54.74%
Rev. gr., 5y
%
Revenues
5m
31,894,11463,909,000113,160,000113,160,0000000000004,800,000
Net income
-61m
L+221.18%
2,096,9610000-14,400,000-15,841,000-24,352,000-18,507,000-26,806,000-30,932,000-28,144,000-18,872,000-60,614,000
CFO
-23m
L-13.84%
11,463,1100000-14,168,000-14,513,000-20,547,000-24,192,000-22,666,000-23,206,000-23,573,000-26,240,000-22,608,000
Earnings
Feb 04, 2025

Profile

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
URL
https://www.biolinerx.com/
IPO date
Jan 30, 2007
Employees
49
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,800
 
Cost of revenue
47,441
29,811
25,437
Unusual Expense (Income)
NOPBT
(42,641)
(29,811)
(25,437)
NOPBT Margin
Operating Taxes
1,000
(6,079)
1,090
Tax Rate
NOPAT
(42,642)
(23,732)
(26,527)
Net income
(60,614)
221.18%
(18,872)
-32.94%
(28,144)
-9.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
14,089
14,359
50,407
BB yield
-209.59%
-707.52%
-838.64%
Debt
Debt current
3,673
1,969
2,925
Long-term debt
9,736
12,511
3,620
Deferred revenue
Other long-term liabilities
11,932
4,509
1,859
Net debt
(29,585)
(36,602)
(50,590)
Cash flow
Cash from operating activities
(22,608)
(26,240)
(23,573)
CAPEX
(297)
(316)
(97)
Cash from investing activities
1,444
4,006
(38,224)
Cash from financing activities
15,056
20,438
57,749
FCF
(42,032)
(23,947)
(26,114)
Balance
Cash
42,994
51,082
57,135
Long term investments
Excess cash
42,754
51,082
57,135
Stockholders' equity
(342,259)
(289,543)
(272,234)
Invested Capital
379,005
357,217
346,831
ROIC
ROCE
EV
Common stock shares outstanding
64,224
51,597
44,196
Price
0.10
166.10%
0.04
-71.08%
0.14
-19.05%
Market cap
6,722
231.22%
2,029
-66.23%
6,011
112.25%
EV
(22,863)
(34,573)
(44,579)
EBITDA
(41,257)
(29,157)
(24,734)
EV/EBITDA
0.55
1.19
1.80
Interest
2,169
2,158
984
Interest/NOPBT